R M Gulick
Affiliation: Cornell University
- Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-upR M Gulick
Department of Medicine, New York University School of Medicine, New York, USA
JAMA 280:35-41. 1998..Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients...
- 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudineR M Gulick
Weill Medical College of Cornell University, New York, New York, USA
Ann Intern Med 133:35-9. 2000..Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known...
- The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)J J Eron
Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
J Infect Dis 181:1622-8. 2000..Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1...
- Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359R M Gulick
Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 182:1375-84. 2000..18%; P=.002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen...
- Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373R M Gulick
Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
J Infect Dis 183:715-21. 2001..7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression...
- Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV diseaseB H Lerner
Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Ann Intern Med 129:573-8. 1998..Encouraging the active participation of HIV-positive persons in their own treatment will help avoid judgmental and inaccurate assessments of patient behavior and may help patients take medications more successfully...
- New antiretroviral drugsR M Gulick
Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
Clin Microbiol Infect 9:186-93. 2003..Investigational HIV integrase inhibitors include S-1360. Continued progress in the treatment of HIV disease will result from the development of new antiretroviral drugs...